Text size A - A+

RSS

FOR RELEASE 5/1/2013, Wednesday

Bausch + Lomb to Present Wealth of Data at the Association for Research in Vision and Ophthalmology Annual Meeting

19 Poster Presentations Examine Current and Potential Ophthalmic Products, 

Subjects of Interest to the Eye Health Community

ROCHESTER, NY — Bausch + Lomb, the global eye health company, will present 19 scientific posters at the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting (Seattle, Wa, May 5-9).  The poster presentations will highlight the results of research on a wide variety of current and potential product offerings, as well as topics of interest to ophthalmic professional community. 

“We are committed to conducting research that helps further understanding of our current products, investigates relevant issues, and explores the possibilities of potential future therapies,” said Cal Roberts, M.D., chief medical officer, Bausch + Lomb. “ARVO provides a great forum to share this research and foster a dialogue that may ultimately lead to better patient outcomes.”

Among the 19 posters being presented, three of particular interest highlight:

  • 2012 results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, which monitors the potency of a variety of common antibiotics against ocular pathogens;
  • Biocidal efficacy of various multipurpose solutions against Gram negative organisms associated with corneal infiltrative events;
  • The use of computer eye modeling in the design process of multifocal contact lenses.

The complete schedule (by topic) for all Bausch + Lomb supported poster presentations is as follows:

Ocular Infection
2886 - B0255. Prevalence and characteristics of MRSA from clinical conjunctivitis trials versus ocular surveillance studies T.W. Morris; C.M. Sanfilippo; C.K. Hesje; M.E. MacGilvray; W. Haas [Tuesday, May 7, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Clinical and Translational Studies in Ocular Infection and Immunity]

2904 - B0273. Antibiotic Resistance Surveillance of Ocular Pathogens - four years of ARMOR Study Results W. Haas; J. Deane; T.W. Morris; D.F. Sahm [Tuesday, May 7, 8:30 – 10:15 am, Exhibit/Poster Hall, Clinical and Translational Studies in Ocular Infection and Immunity]

5222 - C0141. Genomics of the Conjunctival Pathogen Streptococcus pneumoniae M. Valentino; W. Haas; C.M. Sanfilippo; J.W. Rosch; E.I. Tuomanen; T.W. Morris; M.S. Gilmore [Wednesday, May 8, 2:45 - 4:30 p.m., Exhibit/Poster Hall, Corneal Infection/Inflammation I]

5450 - A0149. Atypical Pathogens Observed in Recent Clinical Studies of Bacterial Conjunctivitis L.S. Gearinger; C.M. Sanfilippo; L. Zhang; W. Haas; T.L. Comstock; T.W. Morris [Thursday, May 9, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Ocular Surface in Health and Disease]

Ocular Inflammation
99 - C0104. Zylet® (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared with Tobradex (dexamethasone 0.1%/tobramycin 0.3%) for the Treatment of Lid Inflammation in Two Populations T.L. Comstock; H.H. DeCory; K. Bateman [Sunday, May 5, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Inflammation and Drugs]

111 - C0116. Comparison of effects between glucocorticoids and mapracorat after repeat topical ocular administration in rabbits for 28 days K. Krenzer; S. Jiang; E.R. Lowe; M. Richardson [Sunday, May 5, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Inflammation and Drugs]

123 - C0128. 24-Hour Evaluation of the Ocular Pharmacokinetics of 14C-Labeled Low-Concentration, Modified Bromfenac Ophthalmic Solution Following Topical Instillation into the Eyes of New Zealand White Rabbits G. Baklayan [Sunday, May 5, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Inflammation and Drugs]

125 - C0130. Randomized, Placebo-Controlled, Integrated Phase III Clinical Trials of a Once Daily, Low-Concentration, Modified Bromfenac Ophthalmic Solution Following Cataract Surgery: Focus on Zero to Trace Anterior Chamber Inflammation J.A. Gow; J.D. Boyce; H.J. Reiser; R. Berry; J.T. Dao; S.P. Chandler [Sunday, May 5, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Inflammation and Drugs]

5399 - A0043. Induction of MAPK Phosphatase-1 by the Novel Selective Glucocorticoid Receptor Agonist Mapracorat Suppresses Inflammatory Signaling Pathways in Human Corneal Epithelial Cells M.E. Cavet; K.L. Harrington; T.R. Vollmer; M. Richardson; J. Zhang [Thursday, May 9, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Anterior Eye: Physiology and Pharmacology]

6029 - A0092. Inhibition of Matrix Metalloproteinases by Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist (SEGRA), in Human Corneal Epithelial Cells T.R. Vollmer; K.L. Harrington; J. Zhang; M. Richardson; M.E. Cavet [Thursday, May 9, 10:30 – 12:15 a.m., Exhibit/Poster Hall, Dry Eye and Lacrimal Gland V]

Glaucoma
460 - A0191. Latanoprostene Bunod 0.024% Significantly Reduces and Maintains Mean Diurnal Intra-Ocular Pressure (IOP) Compared to Latanoprost 0.005% in Subjects with Open Angle Glaucoma or Ocular Hypertension L. Katz; P.L. Kaufman; T. Ong; B. Scassellati- Sforzolini; J.L. Vittitow  [Sunday,
May 5, 10:30 – 12:15 p.m., Exhibit/Poster Hall, Neuroprotection; Clinical Drug Studies]

Contact Lenses and Lens Care
487 - B0124. Evaluation of Surface Water Characteristics of Novel Daily Disposable Contact Lenses Using Refractive Index Shifts after Wear J. Schafer; R.B. Steffen [Sunday, May 5, 10:30 – 12:15 p.m. Exhibit/Poster Hall, Contact Lens I]

504 - B0141. Comparative Cleaning Ability of Rigid Gas Permeable Lens Care Systems K.A. Millard; S.F. Groemminger [Sunday, May 5, 10:30 - 12:15 p.m., Exhibit/Poster Hall, Contact Lens I]

506 – B0143. Adhesion of Stenotrophomonas maltophilia, Delftia acidovorans and Achromobacter xylosoxidans to contact lenses A. Vijay; M.D. Willcox [Sunday, May 5, 10:30 – 12:15 p.m., Exhibit/Poster Hall]

510 - B0147. The Antimicrobial Efficacy of Human Tear Proteins after Repeated Exposure to Contact Lens Solutions B.L. Price; P.B. Morgan; C. Maldonado-Codina; C.B. Dobson [Sunday, May 5, 10:30 - 12:15 p.m., Exhibit/Poster Hall, Contact Lens I]

519 - B0156. Disinfection Efficacy of Rigid Gas Permeable Lens Care Systems S.F. Groemminger; D. Callahan [Sunday, May 5, 10:30 – 12:15 p.m., Exhibit/Poster Hall, Contact Lens I]

521 – B0158. The Evaluation of the Biocidal Efficacy of Multi-Purpose Solutions Against Mixed Cultures of Pseudomonas aeruginosa with a Variety of Individual Fungal Organisms J.M. Burger; D. McGrath; B.C. David. [Sunday, May 5, 10:30 – 12:15 p.m., Exhibit/Poster Hall]

5476 - A0175. Determination of Oxygen Permeability of Soft Contact Lenses Using Polarographic Lens Stacking and Single-Lens with Various Powers X. Liu; G.L. Oltean [Thursday, May 9, 8:30 - 10:15 a.m., Exhibit/Poster Hall, Contact Lens II]

5484 - A0183. Designing Multifocal Contact Lenses using a Novel Through-Focus Image Quality Metric Highly Correlated with Clinical Visual Acuity N. Mohan; A.C. Kingston; I.G. Cox [Thursday, May 9, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Contact Lens II]

About Bausch + Lomb
Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.  Founded in 1853, our company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide.
 
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
All other brand/product names are trademarks of their respective owners.
© Bausch & Lomb Incorporated

# # #

News Media Contacts
Teresa Panas
Global Pharmaceutical Communicatons, Bausch + Lomb
+1 (973) 360-6382, +1 (862) 579-7186 or teresa.panas@bausch.com

Jane Mazur
Global Consumer Communications, Bausch + Lomb
+1 (585) 338-5636, +1 (585) 355-5978 or jane.mazur@bausch.com
 
Tad Heitmann
BioComm Network, on behalf of Bausch + Lomb
+1 (714) 273-2937 or theitmann@biocommnetwork.com